prazosin has been researched along with Alcohol Drinking in 24 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
Alcohol Drinking: Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Prazosin treatment before stresses experienced during alcohol deprivations may prevent the increased anxiety during subsequent deprivation/abstinence that is a risk factor for relapse to alcohol drinking." | 7.85 | Prazosin Prevents Increased Anxiety Behavior That Occurs in Response to Stress During Alcohol Deprivations. ( Froehlich, JC; Kincaid, CL; Rasmussen, DD, 2017) |
| "Prazosin (PRZ; an α1 -adrenergic receptor antagonist) and naltrexone (NTX; a nonspecific opioid receptor antagonist) each decrease alcohol drinking when administered to rats selectively bred for high voluntary alcohol drinking (alcohol-preferring or "P"), and the combination of PRZ + NTX decreases alcohol drinking more effectively than does either drug alone." | 7.81 | Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals. ( Froehlich, JC; Kincaid, CL; Rasmussen, DD, 2015) |
| "Alcohol drinking following propranolol treatment was variable, but the combination of propranolol + prazosin consistently suppressed alcohol drinking during both alcohol withdrawal and following prolonged imposed abstinence, and the combination of these 2 drugs was more effective than was treatment with either drug alone." | 7.80 | Combining the α1 -adrenergic receptor antagonist, prazosin, with the β-adrenergic receptor antagonist, propranolol, reduces alcohol drinking more effectively than either drug alone. ( Beckwith, LE; Froehlich, JC; Kincaid, CL; Rasmussen, DD, 2014) |
| "This study examined whether prazosin reduces alcohol drinking over the course of prolonged treatment and whether it blocks the initiation of alcohol drinking in rats with a genetic predisposition toward high alcohol drinking, that is alcohol-preferring (P) rats." | 7.79 | Prazosin reduces alcohol drinking throughout prolonged treatment and blocks the initiation of drinking in rats selectively bred for high alcohol intake. ( Federoff, DL; Fischer, SM; Froehlich, JC; Hausauer, BJ; Rasmussen, DD, 2013) |
| " Given that NTX and prazosin can each reduce alcohol drinking in rats selectively bred for alcohol preference and high voluntary alcohol drinking (alcohol-preferring "P" rats), we tested whether a combination of NTX + prazosin is more effective in decreasing alcohol drinking than is either drug alone." | 7.79 | Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone. ( Froehlich, JC; Hausauer, BJ; Rasmussen, DD, 2013) |
| "The results indicate that the noradrenergic system plays a role in mediating alcohol drinking in rats of the P line and suggest that prazosin--a safe, well-characterized, and well-tolerated drug--may be an effective pharmacotherapeutic agent for the treatment of alcohol use disorders." | 7.75 | The alpha1-adrenergic receptor antagonist, prazosin, reduces alcohol drinking in alcohol-preferring (P) rats. ( Alexander, LL; Froehlich, JC; Raskind, MA; Rasmussen, DD, 2009) |
| " CIE/FSS treatment increased anxiety, which was blocked by treatment with the α1-AR inverse agonist prazosin." | 3.96 | Noradrenergic tone mediates marble burying behavior after chronic stress and ethanol. ( Blandino, KL; den Hartog, CR; Grampetro, MA; Moorman, DE; Nash, ML; Sjogren, ER; Vazey, EM, 2020) |
| "Prazosin treatment before stresses experienced during alcohol deprivations may prevent the increased anxiety during subsequent deprivation/abstinence that is a risk factor for relapse to alcohol drinking." | 3.85 | Prazosin Prevents Increased Anxiety Behavior That Occurs in Response to Stress During Alcohol Deprivations. ( Froehlich, JC; Kincaid, CL; Rasmussen, DD, 2017) |
| "Prazosin decreases alcohol intake in P rats even in a situation that would be expected to increase alcohol drinking, namely following periods of alcohol deprivation." | 3.81 | Prazosin Reduces Alcohol Intake in an Animal Model of Alcohol Relapse. ( Fischer, S; Froehlich, JC; Hausauer, B; Rasmussen, DD; Wise, B, 2015) |
| "Prazosin (PRZ; an α1 -adrenergic receptor antagonist) and naltrexone (NTX; a nonspecific opioid receptor antagonist) each decrease alcohol drinking when administered to rats selectively bred for high voluntary alcohol drinking (alcohol-preferring or "P"), and the combination of PRZ + NTX decreases alcohol drinking more effectively than does either drug alone." | 3.81 | Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals. ( Froehlich, JC; Kincaid, CL; Rasmussen, DD, 2015) |
| "Alcohol drinking following propranolol treatment was variable, but the combination of propranolol + prazosin consistently suppressed alcohol drinking during both alcohol withdrawal and following prolonged imposed abstinence, and the combination of these 2 drugs was more effective than was treatment with either drug alone." | 3.80 | Combining the α1 -adrenergic receptor antagonist, prazosin, with the β-adrenergic receptor antagonist, propranolol, reduces alcohol drinking more effectively than either drug alone. ( Beckwith, LE; Froehlich, JC; Kincaid, CL; Rasmussen, DD, 2014) |
| " Given that NTX and prazosin can each reduce alcohol drinking in rats selectively bred for alcohol preference and high voluntary alcohol drinking (alcohol-preferring "P" rats), we tested whether a combination of NTX + prazosin is more effective in decreasing alcohol drinking than is either drug alone." | 3.79 | Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone. ( Froehlich, JC; Hausauer, BJ; Rasmussen, DD, 2013) |
| "Previous studies show that prazosin, an α(1) -adrenergic receptor antagonist, decreases alcohol drinking in animal models of alcohol use and dependence [Rasmussen et al." | 3.78 | Effects of prazosin, an α1-adrenergic receptor antagonist, on the seeking and intake of alcohol and sucrose in alcohol-preferring (P) rats. ( Czachowski, CL; Froehlich, JC; Rasmussen, DD; Verplaetse, TL, 2012) |
| "To address this aspect of alcohol use disorder, 102 active-duty soldiers participating in command-mandated Army outpatient alcohol treatment were randomized to also receive the brain-penetrant alpha-1 adrenergic receptor antagonist prazosin or placebo for 13 weeks." | 3.30 | A randomized controlled clinical trial of prazosin for alcohol use disorder in active duty soldiers: Predictive effects of elevated cardiovascular parameters. ( Crews, L; Daniels, C; Darnell, J; Goke, K; Hart, K; Hendrickson, R; Holmes, H; Mayer, C; Peskind, ER; Poupore, EL; Raskind, MA; Rasmussen, D; Saxon, A; Simpson, T; Terry, G; Thomas, RG; Williams, T, 2023) |
| "In Study 1, patients with Alcohol Use Disorder (AUD) (N = 45) with varying AW levels at treatment entry were assessed to examine AW effects on corticostriatal responses to stress, alcohol cue and neutral visual images with functional magnetic resonance imaging (fMRI)." | 3.11 | Alcohol withdrawal symptoms predict corticostriatal dysfunction that is reversed by prazosin treatment in alcohol use disorder. ( Angarita, G; Fogelman, N; Hermes, G; Seo, D; Sinha, R; Wemm, S, 2022) |
| "Veterans with comorbid alcohol dependence and PTSD (n = 96) were randomized to prazosin (16 mg) or placebo in a 12-week outpatient, double-blind clinical trial." | 2.90 | Alcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder. ( Gueorguieva, R; McKee, SA; Petrakis, IL; Ralevski, E; Roberts, W; Verplaetse, TL, 2019) |
| " Medication was titrated to a target dosing schedule of 4 mg in the morning, 4 mg in the afternoon, and 8 mg at bedtime by the end of week 2." | 2.87 | Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder. ( Lyons, R; Malte, CA; Millard, SP; Raskind, M; Saxon, AJ; Simpson, TL; Stappenbeck, C; Tell, D, 2018) |
| "Within the PTSD group, combat exposure was associated with increased drinking independent of the severity of PTSD symptoms." | 2.79 | Characteristics and drinking patterns of veterans with alcohol dependence with and without post-traumatic stress disorder. ( Arias, AJ; Fuehrlein, B; Jane, JS; O'Brien, E; Petrakis, IL; Ralevski, E, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.17) | 18.7374 |
| 1990's | 1 (4.17) | 18.2507 |
| 2000's | 1 (4.17) | 29.6817 |
| 2010's | 16 (66.67) | 24.3611 |
| 2020's | 5 (20.83) | 2.80 |
| Authors | Studies |
|---|---|
| Sinha, R | 3 |
| Andrade, C | 1 |
| Fogelman, N | 1 |
| Wemm, S | 1 |
| Angarita, G | 1 |
| Seo, D | 1 |
| Hermes, G | 1 |
| Raskind, MA | 2 |
| Williams, T | 1 |
| Holmes, H | 1 |
| Hart, K | 1 |
| Crews, L | 1 |
| Poupore, EL | 1 |
| Thomas, RG | 1 |
| Darnell, J | 1 |
| Daniels, C | 1 |
| Goke, K | 1 |
| Hendrickson, R | 1 |
| Terry, G | 1 |
| Mayer, C | 1 |
| Simpson, T | 1 |
| Saxon, A | 1 |
| Rasmussen, D | 1 |
| Peskind, ER | 1 |
| den Hartog, CR | 1 |
| Blandino, KL | 1 |
| Nash, ML | 1 |
| Sjogren, ER | 1 |
| Grampetro, MA | 1 |
| Moorman, DE | 1 |
| Vazey, EM | 1 |
| Simpson, TL | 2 |
| Saxon, AJ | 2 |
| Stappenbeck, C | 1 |
| Malte, CA | 1 |
| Lyons, R | 1 |
| Tell, D | 1 |
| Millard, SP | 1 |
| Raskind, M | 2 |
| Verplaetse, TL | 2 |
| Ralevski, E | 2 |
| Roberts, W | 1 |
| Gueorguieva, R | 1 |
| McKee, SA | 1 |
| Petrakis, IL | 2 |
| Kleinman, RA | 1 |
| Ostacher, MJ | 1 |
| Froehlich, JC | 8 |
| Hausauer, BJ | 2 |
| Federoff, DL | 1 |
| Fischer, SM | 1 |
| Rasmussen, DD | 8 |
| Fuehrlein, B | 1 |
| O'Brien, E | 1 |
| Jane, JS | 1 |
| Arias, AJ | 1 |
| Beckwith, LE | 1 |
| Kincaid, CL | 3 |
| Skelly, MJ | 2 |
| Weiner, JL | 2 |
| Chappell, AE | 1 |
| Carter, E | 1 |
| Hausauer, B | 1 |
| Fischer, S | 1 |
| Wise, B | 1 |
| Funk, D | 1 |
| Coen, K | 1 |
| Tamadon, S | 1 |
| Li, Z | 1 |
| Loughlin, A | 1 |
| Lê, AD | 1 |
| Alexander, LL | 1 |
| Czachowski, CL | 1 |
| Miyamae, M | 1 |
| Camacho, SA | 1 |
| Zhou, HZ | 1 |
| Diamond, I | 1 |
| Figueredo, VM | 1 |
| Aalto, J | 1 |
| Kiianmaa, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of RBP-7000 as a Treatment in Subjects With Acute Schizophrenia Over 8 Weeks (2 Subcutaneous Doses)[NCT02109562] | Phase 3 | 354 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| Clinical Trial of the Adrenergic Alpha-1 Antagonist Prazosin for Alcohol Dependence[NCT00762710] | Phase 2 | 92 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Open Label 8-Week Study of Prazosin Use in Adults With Anxiety Disorders[NCT03894345] | Phase 1 | 20 participants (Anticipated) | Interventional | 2019-05-24 | Suspended (stopped due to COVID-19) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The CGI-S rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to Normal, not at all ill and a rating of 7 is equivalent to Among the most extremely ill participants. Negative change from baseline scores indicate improvement in the severity of illness.~Estimates (least square means and standard errors), 2-sided confidence intervals, and -1-sided P values are based on a repeated-measures linear regression model of the change from baseline score, with fixed effects for visit as a categorical variable, baseline score, treatment and treatment by visit interaction, assuming an unstructured covariance matrix." (NCT02109562)
Timeframe: Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| RBP-7000 90 mg | -0.868 |
| RBP-7000 120 mg | -0.914 |
| Placebo | -0.518 |
"The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor judgement, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 PANSS items and ranges from 30 to 210, with 30 indicating absence of symptoms of schizophrenia and 210 indicating extreme ratings of all 30 symptoms. Negative change from baseline scores indicate improvements in symptoms.~Estimates (least square means and standard errors), 2-sided confidence intervals, and -1-sided P values are based on a repeated-measures linear regression model of the change from baseline score, with fixed effects for visit as a categorical variable, baseline score, treatment and treatment by visit interaction, assuming an unstructured covariance matrix." (NCT02109562)
Timeframe: Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| RBP-7000 90 mg | -15.367 |
| RBP-7000 120 mg | -16.456 |
| Placebo | -9.219 |
"An adverse event (AE) is defined as any study-related event that represents a change (positive or negative) in frequency or severity from a baseline (prestudy) event (if any), regardless of the presence of causal relationship or medical significance. Treatment-emergent adverse events are defined as any adverse event with a start date on or after the first study dose date. AEs are determined by the Investigator to be related or not related to the study drug.~A serious AE (SAE) is defined by federal regulation as any AE occurring at any dose that results in any of the following outcomes: death, life-threatening AE, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect. Although a subject may have had 2 or more adverse experiences the subject is counted only once in a category. The same subject may appear in different categories." (NCT02109562)
Timeframe: Day 1 to Week 8
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| No TEAEs | 1 or more TEAEs | Related TEAE | Serious TEAE | Serious, related TEAE | TEAE causing discontinuation | Death | |
| Placebo | 37 | 81 | 50 | 1 | 0 | 3 | 0 |
| RBP-7000 120 mg | 26 | 91 | 65 | 1 | 0 | 2 | 0 |
| RBP-7000 90 mg | 34 | 81 | 58 | 0 | 0 | 0 | 0 |
At the baseline and final medication visits, the Form 90 (19) was used to assess alcohol and drug use for the preceding 90-day period (NCT00762710)
Timeframe: 12 weeks
| Intervention | percentage of days heavy drinking (Mean) | |
|---|---|---|
| Baseline % Days Heavy Drinking | Final medication week % Days Heavy Drinking | |
| Placebo | 66.5 | 22.6 |
| Prazosin | 71.8 | 11.4 |
5 trials available for prazosin and Alcohol Drinking
| Article | Year |
|---|---|
Alcohol withdrawal symptoms predict corticostriatal dysfunction that is reversed by prazosin treatment in alcohol use disorder.
Topics: Alcohol Drinking; Alcoholism; Craving; Humans; Prazosin; Substance Withdrawal Syndrome | 2022 |
A randomized controlled clinical trial of prazosin for alcohol use disorder in active duty soldiers: Predictive effects of elevated cardiovascular parameters.
Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Ethanol; Humans; Military Personnel; Prazosin; Su | 2023 |
Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder.
Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Double-Blind Method; Drug Adm | 2018 |
Alcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Alcohol Abstinence; Alcohol Drinking; Alcoholi | 2019 |
Characteristics and drinking patterns of veterans with alcohol dependence with and without post-traumatic stress disorder.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Alcohol Drinking; Alcoholism; Comorbidity; Co | 2014 |
19 other studies available for prazosin and Alcohol Drinking
| Article | Year |
|---|---|
Prazosin for Alcohol Use Disorder: A Clarification.
Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Humans; Prazosin | 2021 |
Prazosin for Alcohol Use Disorder: Reply to Sinha.
Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Humans; Prazosin | 2021 |
Noradrenergic tone mediates marble burying behavior after chronic stress and ethanol.
Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Animals; Anxiety; Ethanol; Female; Locus | 2020 |
Prazosin for the Treatment of Alcohol Use Disorders.
Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Humans; Prazosin | 2018 |
Prazosin for Alcohol Use Disorder: Response to Kleinman and Ostacher.
Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Humans; Prazosin | 2019 |
Prazosin and Alcohol Use Disorder.
Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Humans; Prazosin | 2019 |
Prazosin reduces alcohol drinking throughout prolonged treatment and blocks the initiation of drinking in rats selectively bred for high alcohol intake.
Topics: Alcohol Drinking; Animals; Breeding; Dose-Response Relationship, Drug; Ethanol; Male; Prazosin; Rand | 2013 |
Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Animals | 2013 |
Combining the α1 -adrenergic receptor antagonist, prazosin, with the β-adrenergic receptor antagonist, propranolol, reduces alcohol drinking more effectively than either drug alone.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Alcohol Drinking; Alcoholism; | 2014 |
Chronic treatment with prazosin or duloxetine lessens concurrent anxiety-like behavior and alcohol intake: evidence of disrupted noradrenergic signaling in anxiety-related alcohol use.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic Uptake Inhibitors; Alcohol Drinking; Animals; An | 2014 |
Adolescent social isolation increases anxiety-like behavior and ethanol intake and impairs fear extinction in adulthood: Possible role of disrupted noradrenergic signaling.
Topics: Aging; Alcohol Drinking; Animals; Anti-Anxiety Agents; Anxiety; Central Nervous System Depressants; | 2015 |
Prazosin Reduces Alcohol Intake in an Animal Model of Alcohol Relapse.
Topics: Alcohol Abstinence; Alcohol Drinking; Alcoholism; Animals; Disease Models, Animal; Male; Prazosin; R | 2015 |
Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals.
Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Animals; Drug Therapy, Combin | 2015 |
Effects of prazosin and doxazosin on yohimbine-induced reinstatement of alcohol seeking in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Alcohol Drinking; Animals; Br | 2016 |
Prazosin Prevents Increased Anxiety Behavior That Occurs in Response to Stress During Alcohol Deprivations.
Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Animals; Anxiety; Dose-Response Relations | 2017 |
The alpha1-adrenergic receptor antagonist, prazosin, reduces alcohol drinking in alcohol-preferring (P) rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Alcohol Drinking; Animals; Da | 2009 |
Effects of prazosin, an α1-adrenergic receptor antagonist, on the seeking and intake of alcohol and sucrose in alcohol-preferring (P) rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Animals; Appetitive Behavior; Central Ner | 2012 |
Alcohol consumption reduces ischemia-reperfusion injury by species-specific signaling in guinea pigs and rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Blood Pressure; Coronary Circulation; Creatine Kinase; Diasto | 1998 |
Role of brain monoaminergic systems in the increased ethanol drinking caused by REM-sleep deprivation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Drinking; Animals; Brain Chemistry; Catecholamines; Citalopr | 1987 |